Browsing by Author "Dong, Edward"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer
    (American Society of Clinical Oncology, 2022) Dong, Chuanpeng; Reiter, Jill L.; Dong, Edward; Wang, Yue; Lee, Kelvin P.; Lu, Xiongbin; Liu, Yunlong; BioHealth Informatics, School of Informatics and Computing
    Purpose: High tumor mutation burden (TMB) in many cancer types is associated with the production of tumor-specific neoantigens, a favorable outcome and response to immune checkpoint blockade (ICB) therapy. Besides mutation-derived neoantigens, aberrant intron retention also produces tumor neopeptides that could trigger an immune response. The relationship between intron-retention-derived tumor neoantigens (IR-neoAg) and clinical outcomes in pancreatic cancer remains uncertain. Here, we quantify IR-neoAg in pancreatic cancer and evaluate whether IR-neoAg load might serve as a biomarker for selecting patients who may benefit from ICB therapy. Methods: We developed a computational approach to estimate patient-specific IR-neoAg load from transcriptome data available in The Cancer Genome Atlas pancreatic cancer cohort. Associations between IR-neoAg load and patient overall survival were evaluated using Kaplan-Meier estimates and Cox regression. Differential expression of immune checkpoint and HLA-I genes was evaluated in tumors with high IR-neoAg load. Results: High IR-neoAg load predicted better overall survival in pancreatic cancer, although no association was found for TMB. IR-neoAg load remained a significant prognostic factor after adjusting for patient age, sex, tumor stage and grade, and TMB. Moreover, pancreatic tumors with both high IR-neoAg load and high HLA-I gene expression had similar gene expression profiles as other tumor types that showed response to anti-programmed cell death protein 1 therapy. Conclusion: IR-neoAg load is associated with favorable survival in pancreatic cancer. These findings provide strong evidence for considering IR-neoAgs when selecting patients who might benefit from ICB therapy.
  • Thumbnail Image
    Item
    MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
    (The American Society for Clinical Investigation, 2021-01-07) Fang, Yuanzhang; Wang, Lifei; Wan, Changlin; Sun, Yifan; Van der Jeught, Kevin; Zhou, Zhuolong; Dong, Tianhan; So, Ka Man; Yu, Tao; Li, Yujing; Eyvani, Haniyeh; Colter, Austyn B.; Dong, Edward; Cao, Sha; Wang, Jin; Schneider, Bryan P.; Sandusky, George E.; Liu, Yunlong; Zhang, Chi; Lu, Xiongbin; Zhang, Xinna; Medical and Molecular Genetics, School of Medicine
    Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell-mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.
  • Thumbnail Image
    Item
    Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway
    (Elsevier, 2019-10-01) Liu, Yunjian; Kim, Hyeong Geug; Dong, Edward; Dong, Chuanpeng; Huang, Menghao; Liu, Yunlong; Liangpunsakul, Suthat; Dong, Xiaocheng Charlie; Biochemistry and Molecular Biology, School of Medicine
    Sestrin 3 (Sesn3) belongs to a small protein family that has been implicated in multiple biological processes including anti-oxidative stress, anti-aging, cell signaling, and metabolic homeostasis. However, the role of Sesn3 in hepatocellular carcinoma (HCC) remains unclear. Here we generated a Sesn3 knockout mouse model and induced HCC development by a combination of a single dose of diethylnitrosamine and chronic feeding of a choline deficient-high fat diet. After 6 months of the dietary treatment, Sesn3 knockout mice developed more severe HCC with higher levels of alpha-fetoprotein, arginase 1, and cytokeratin 19, but also higher metastatic rates than wild-type mice. Histological analysis revealed elevated extracellular matrix and cancer stem cell markers including Acta2, Cd44, and Cd133. Signaling analysis showed activated IL6-Stat3 and Akt pathways. Biochemical and microscopic analyses uncovered a novel inhibitory regulation of Gli2, a downstream transcription factor of the hedgehog signaling, by Sesn3. Two of the Gli2-regulated genes – Pdgfrb and Cd44 were upregulated in the Sesn3-deficient liver tissue. In conclusion, our data suggest that Sesn3 plays a critical tumor suppressor role in the liver partly through the inhibition of the hedgehog signaling.